What is enterprise valuation (EV)?
Valuation is the process of determining the current or projected worth of a business or its assets, based on financial performance, market potential, intellectual property, and other tangible or intangible factors.
Running a technology-based startup requires a range of skills, both technical and non-technical. Among the most challenging and often overlooked aspects is valuation: the science and art of determining a business’s worth. It’s a critical skill rarely covered in entrepreneurship training (or even at business school), yet essential for founders navigating growth, investment, and partnerships.
Why is valuation important?
Valuation underpins almost every aspect of a business.
Different types of stakeholders want to see a rationale for engaging with a company, whether it’s an investor evaluating potential returns, a partner exploring synergies, or regulators and payers considering market impact. A strong valuation story makes a business case more compelling and easier to champion.
- Strategic Planning: Objective valuations highlight key value drivers and weaknesses, guiding resource allocation and investment decisions. This helps founders track progress toward financial and strategic goals. Every stakeholder weighs risk against reward. A robust valuation framework reassures investors and partners that risks are well understood and managed.
- Establishing Credibility: A clear, defensible valuation demonstrates professionalism and strategic maturity. Whether speaking with investors, customers, partners, or employees, being able to articulate value signals that you’re building a viable and valuable business. This signals confidence and generates momentum around a startup, attracting multiple suitors.
- Facilitating Deal Structuring: From equity rounds to licensing agreements and revenue-sharing models, accurate valuation supports flexible, transparent deal-making. Knowing what technology, data, market traction, or IP is worth helps structure deals that meet the needs of all parties.
- Negotiating Power: Valuation sets the foundation for every negotiation, from equity investment and licensing deals to strategic hires or employee stock options. Knowing value ensures founders don’t give away too much and helps secure fair terms that protect long-term growth.
Valuation methods
There are various approaches that companies can take to valuing their enterprises. Often, there is no single “best†method available, and companies will use two or more different approaches to generate a range of values.
The method chosen depends on the stage of the company and the data available to support a valuation:
- For earlier-stage startups with higher uncertainty, valuation is often based on future potential rather than past financial performance.
- For later-stage, revenue-generating companies, more data (revenues, customer metrics, milestones) reduces risk and increases valuation accuracy.
- EBITDA Multiple Method: This approach applies an industry-specific multiple to a company’s EBITDA, calculated over 3-5 years. It provides a realistic picture of profitability potential but is less effective for companies still in their early growth stages or those that do not generate a profit. This is the most common valuation method across all sectors and is simple to apply.
- Revenue Multiple Method: This method bases valuation on applying industry-specific multiples to annual recurring revenue (ARR) or total revenue. It’s simple, quick, and works best for startups with strong growth and recurring revenue, though it doesn’t account for profitability or cash flow.
- Discounted Cash Flow (DCF) Method: This method projects future cash flows and discounts them to present value using a rate often set high for startups. It works best for companies with predictable revenue or long-term contracts, as it captures intrinsic value. However, it is highly sensitive to assumptions and challenging to apply when revenue is unstable. DCF is routinely used in combination with multiples methods to get a more accurate valuation.
- Venture Capital (VC) Method: The VC Method projects the startup’s exit value and discounts it to present value using expected return on investment (ROI) for investors. It’s designed for startups targeting external investment, providing a framework for negotiation, but results are highly sensitive to assumptions about exit timing and market conditions.
What is pre-revenue valuation?
Pre-revenue valuation is the process of estimating the worth of a startup before it generates significant sales or cash flow. It relies on qualitative factors, such as potential and risk, and comparable benchmarks rather than financial performance.
- Berkus Method: The Berkus Method provides a quick, scorecard-style valuation for very early-stage startups with no revenue. It assigns a value to five qualitative success factors, typically totalling $2–2.5M. Simple and intuitive, it works best for startups without market traction but lacks precision due to subjective estimates.
- Scorecard Method: This method compares a startup to similar ventures and adjusts for factors that influence potential success. It’s useful for pre-revenue startups raising early capital, as it adds structure to valuation, though it still depends heavily on comparable data and market assumptions.
- Risk Factor Summation Method: Starting from a baseline value (often $2.5M), this approach adjusts valuation based on 12 risk categories, including market, technology, competition, and legal factors. It’s ideal for early-stage startups where risk dominates, but subjective scoring can lead to wide variations in value.
- Cost-to-Duplicate Method: This method estimates how much it would cost to recreate the startup from scratch, including technology, IP, and development efforts. It helps early-stage founders justify their investment but doesn’t account for market traction or growth potential.
What is market-based valuation?
Market-based valuation estimates a startup’s worth by comparing it to other companies or transactions in the same industry. It relies on observable market data, such as revenue, earnings, or deal prices, rather than internal projections.
- Comparable Company Method: This method derives a valuation by comparing financial performance with that of similar companies. It works best for startups with stable revenue in competitive markets where comparable companies can be readily identified. This method accounts for real market conditions, provided that it is based on truly comparable companies.
- Precedent Transactions: This approach derives valuation from recent transactions such as mergers or acquisitions of similar companies. It’s particularly useful for startups in active markets, such as SaaS or MedTech, as it captures market appetite and premium values. The challenge is finding truly comparable transactions to provide a reliable benchmark.
When should you value your startup?
Valuation is not a one-time exercise. Startups must continuously review their valuation in the context of their development and commercialisation activities. However, there are some critical points at which valuations usually occur:
- Internal milestones: Every 12–18 months, or when major events occur (new IP, regulatory or market access milestones, revenue traction).
- Fundraising rounds: Essential when issuing equity or negotiating with investors.
- Strategic partnerships/licensing deals: To benchmark value during negotiations with corporates, distributors, or licensees.
- M&A discussions: If a company is considering an acquisition (or being acquired).
- Employee stock option planning (ESOPs): For setting strike prices or options pool allocations.
- Board/investor reporting: To align on progress and value creation.
Should startups commission valuations or do it themselves?
Startups can choose between hiring a professional consultant or performing a valuation in-house.
DIY Valuation:
Anyone can (and probably should) learn how to value companies and assets. In-house valuations are low-cost, faster, and more flexible, making them ideal for internal planning or preparing for initial conversations with investors.
DIY valuations are particularly suitable for early-stage startups (pre-seed or seed), where financial data is minimal and qualitative factors, such as team, market potential, and IP, drive value.
However, in-house valuations may lack credibility with sophisticated investors, who often expect an independent assessment for larger deals.
Consultant-Commissioned Valuation:
Professionals provide robust methods, often in combination with EBIDTA or revenue multiples, Discounted Cash Flow (DCF), the VC method, and comparables, along with documentation to support negotiations. Recommended for later-stage fundraising, strategic partnerships, or M&A discussions where credibility and defensibility matter. This approach is more costly, but it can prevent disputes and signal professionalism to investors, corporates, or acquirers.
Tip Recommendation: Use regular in-house valuations for planning or small-scale partnerships, and commission professional valuations in preparation for financing rounds, large-scale alliances, M&A, and licensing deals.
Resources
United State of America (USA):
Food and Drug Administration (FDA) guidance document:
European Union (EU):
Medical Devices Regulation (MDR) 2017/745:
- Design and Development is included in the QMS Requirements: Chapter I, Article 10(9)(g)
In Vitro Diagnostic Medical Devices Regulation (IVDR) 2017/746
- Design and Development is included in the QMS Requirements: Chapter I, Article 10(8)(g)
United States of America (USA):
Food and Drug Administration (FDA), Federal Food, Drug, and Cosmetic Act (FD&C Act):
- Technical documentation requirements are specified in the QMS requirements PART 820.30 Quality System Regulation Procedures: Design Controls
International Standards:
ISO 13485:2016: Medical devices - Quality management systems - Requirements for regulatory purposes, Section 7.3. Design and Development
Acceptance Criteria: The predefined standards and specifications that a device must meet during testing and evaluation to be deemed suitable for its intended use and to comply with regulatory requirements.
Change Control: The systematic process of managing and documenting modifications to a device or its manufacturing process to ensure that all changes are assessed, approved, implemented, and tracked in compliance with regulatory standards and quality management systems. This is also known as Change Management.
Clinical Evaluation: A methodologically sound ongoing procedure to collect, appraise, and analyse clinical data about a medical device and to verify its safety and performance, including its clinical benefits. Also see Clinical Investigation.
Conformity Assessment: A process used to determine whether a product, service, system, or entity meets specified standards, regulations, or requirements.
Design Control: A systematic process that ensures a device is designed to meet user needs and intended uses.
Design and Development Plan: A comprehensive document outlining the systematic process and stages, including timelines, responsibilities, and resources, required to bring a medical device from concept to market-ready product, ensuring compliance with regulatory standards.
Design Freeze: The point in the medical device development process where the design is finalised and no further changes are allowed, ensuring a stable basis for validation, regulatory submission, and production.
Design Inputs: The physical and performance requirements of a device that are used as a basis for device design. Also known as Technical Specifications.
Design Outputs: The results of a design effort at each design phase and at the end of the total design effort used to evaluate conformance to design input requirements.
Design Review: A formal evaluation process to assess the completeness, feasibility, and compliance of a device’s design with specified requirements (design inputs).
Design Transfer: The process of transitioning a product’s design from development and manufacturing into production while ensuring all specifications and requirements are met.
Design Verification: The process of ensuring that design outputs meet design inputs.
Design Validation: The process of ensuring that devices conform to defined user needs and intended uses.
ISO 13485: An international standard that specifies requirements for a quality management system (QMS) specific to the medical devices industry.
Manufacturer: A legal entity that designs, produces, assembles, or labels a medical device with the intention of placing it on the market.
Post-Market Surveillance (PMS): The proactive collection and review of experiences and data related to a device after it has been released onto the market to ensure continued safety and performance.
Quality Assurance (QA): The systematic activities implemented to ensure that devices consistently meet regulatory requirements and standards while meeting user needs and expectations.
Quality Management System (QMS): A formalised system that documents the structure, responsibilities, and procedures required to achieve effective quality management.
Record: A documented piece of evidence detailing activities, decisions, or results, created and maintained to demonstrate compliance with regulatory requirements and quality management standards.
Regulation: The rules, laws, standards, and requirements set by regulatory authorities to ensure the safety, efficacy, and quality of devices intended for medical use.
Regulatory Authority: An official body overseeing and enforcing laws, regulations, and standards within a specific industry or sector to ensure compliance and protect public interests. Also known as a Regulatory Authority. Also see Competent Authority and Notified Body.
Regulatory Submission: The formal process of submitting documentation and data to regulatory authorities for review and approval to market or sell the device within a specific jurisdiction.
Risk Management (RM): The systematic application of management policies, procedures, and practices to the tasks of analysing, evaluating, controlling, and monitoring risk.
Safety: The condition of being protected from or unlikely to cause danger, risk, or injury.
Standard: A document that provides guidance, requirements, or specifications established by regulatory bodies, industry organisations, or international consensus groups.
Technical Documentation: All documents that demonstrate the design, manufacture, and performance of the device, essential for ensuring compliance with regulatory requirements. This is also known as the Technical File.
Technical Specifications: Detailed descriptions of the requirements, characteristics, and standards that a product, service, or system must meet or adhere to, ensuring clarity and consistency in its design, production, or implementation. Also see Design Inputs.
Traceability: The ability to verify an item’s history, location, or application by means of documented recorded identification.
Traceability Matrix: A document that maps and links requirements throughout the development lifecycle, ensuring that each requirement is tested and validated, thereby demonstrating compliance with regulatory standards.
User Requirements: The requirements and preferences of the intended users, which must be considered and addressed in the device design. Also known as User Needs or Customer Specifications.